核医学市場：製品タイプ、投与方法、用途、使用性、エンドユーザー別-2025～2030年世界予測

核医学市場の2024年の市場規模は146億米ドルで、2025年には160億5,000万米ドル、CAGR 10.80%で成長し、2030年には270億4,000万米ドルに達すると予測されています。

エグゼクティブサマリー導入：核医学における概要と課題

核医学は現代医療の礎石へと発展し、患者ケアに革命をもたらす斬新な診断・治療ソリューションを提供しています。正確性、精密性、効率性が最重要視されるこの産業において、本エグゼクティブサマリーは現在の情勢を明確かつ包括的に概要しています。技術革新、規制の動向、治療プロトコルのパラダイムの変化など、市場の進化の根底にある重要な要因を取り上げることで、基礎固めを行っています。本書は、意思決定者や産業の専門家を対象とし、新たな動向がどのように臨床の新たなベンチマークを設定し、競合ベンチマーキング戦略を再構築しているかに焦点を当てています。この採用では、慢性疾患の増加、個別化医療の急増、早期診断介入への再注目といった世界の動向が、いかに核医学の革新を促しているかを説明することで、その背景を明らかにしています。世界中の医療システムが先進的な画像診断と治療モダリティへの投資を続ける中、患者の転帰を向上させ、前例のない成長と協力の機会を提供する戦略的再編成の舞台が整いつつあります。

核医学市場の変革

核医学を取り巻く環境は、診断と治療の境界を再定義する変革的なシフトを経験しています。このような変化の主要原動力は、技術的進歩、臨床ガイドラインの進化、規制当局の支援強化であり、これらが一体となって技術革新のペースを加速しています。最も重要な原動力の一つは、より正確なだけでなく患者にとってより安全な最先端の放射性医薬品と画像診断技術の急速な開発です。近年、改良されたデジタル画像技術と強化されたターゲティングメカニズムの融合により、特に腫瘍学、循環器学、神経学などの専門セグメントにおいて、より正確な疾患の検出が可能になりました。

規制機関や医療施策立案者は、新しい診断薬や治療プロトコルの承認プロセスを合理化することで、この変化を促進するのに役立ってきました。このような支援的な枠組みにより、メーカーや研究機関は臨床検査を加速させ、先進的な治療アプローチを日常診療に取り入れることができるようになりました。さらに、画像分析における人工知能と機械学習の統合は、臨床医に洗練された診断ツールを提供し、解釈の精度を高め、疾患の進行に関するより深い洞察を提供しています。

もう一つの注目すべき変化は、個別化医療が重視されるようになってきたことです。個人の遺伝的プロファイルや疾患の特徴に基づいて治療計画をカスタマイズすることは、現代の核医学の中心的な特徴となっています。これは治療成績を向上させるだけでなく、患者の治療における試行錯誤的アプローチを最小限に抑えることによって、医療資源の最適化にも貢献します。このような要因が複合的に影響することで、各患者のユニークなニーズにより機敏に対応できる市場が形成され、診断と治療介入セグメントにおける持続的な成長と革新の舞台が整うことになります。

進化する臨床需要と、他の専門セグメントの中でも特にがん領域における精度の絶え間ない追求は、強固な研究開発イニシアチブの重要性を強調しています。こうした取り組みは、臨床的に実現可能なことの限界を広げ、伝統的薬剤療法と新たな放射性療法を融合させた新しいパラダイムへの道を開くことで、限界を押し広げようとしています。市場が進化を続ける中、利害関係者はデータ主導の考察を活用することで、競合を強化し、患者ケアの新たな基準を設定するための戦略的意思決定を行うようになっています。

市場の意思決定を促進する詳細なセグメンテーション洞察

核医学市場を深く掘り下げたセグメンテーションにより、このセグメントの多様性と複雑化の両方を強調する多面的な構造が明らかになりました。製品タイプ別に見ると、市場は診断用放射性医薬品と治療用核医学に二分されます。診断用放射性医薬品は、陽電子放出断層撮影（PET）アイソトープと単一光子放出コンピュータ断層撮影（SPECT）アイソトープにさらに細分化された画像診断モダリティを包含し、それぞれがユニークな臨床的利点を提供しています。一方、治療核医学は治療に重点を置いているのが特徴で、ブラキセラピー用アイソトープと放射性医薬品治療の2つの主要部門があります。前者は、セシウム-131、ヨウ素-125、イリジウム-192、パラジウム-103などのアイソトープを使用することに重点を置いており、後者はアルファ線放出核種とベータ線放出核種を区別しており、それぞれ特有の放射線生物学的特性と治療用途を持っています。

製品分類にとどまらず、投与方法によるセグメンテーションにより、効果的な治療実施のための重要な考慮事項が浮かび上がります。市場分析では、静脈注射と経口摂取の有効性と患者のコンプライアンスを比較し、治療成果を最大化しながら臨床ニーズを最も満たす投与方法について洞察を提供しています。さらに、用途ベースのセグメンテーションでは、診断手順と治療手順を区別しています。診断領域は、アナログPETとデジタルPETに分類されるPETスキャナーやSPECTスキャナーなどの先進イメージング技術に支えられており、イメージング機器の技術進化と競合力学を浮き彫りにしています。

さらに、用途ベースのセグメンテーションは、循環器科、内分泌科、消化器科、神経科、腫瘍科、整形外科、呼吸器科など、複数の臨床領域を組み込んだ広範な視野を記載しています。各臨床応用領域は、それぞれ異なる臨床課題と機会によって特徴付けられ、核医学がいかに多様な患者のニーズに対応できるように調整されているかを強調しています。これらの臨床専門セグメントを横断的にナビゲートする能力は、診断精度を高めるだけでなく、さまざまな疾患の微妙な特性に対応する、より効果的な治療パラダイムを促進します。

最後に、エンドユーザーによるセグメンテーションは、学術研究機関、診断センター、病院からなる多様なエコシステム概要を示しています。このセグメンテーションにより、医療機関の嗜好や予算上の制約が購買決定や治療プロトコールにどのように影響するかを明らかにし、最終的に核医学セグメントの利害関係者の戦略的優先順位を決定します。このようなセグメンテーション層の影響分析は、核医学の革新が臨床的・商業的に最大限の効果を発揮するよう、的を絞ったマーケティングと販売戦略を支援します。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 慢性疾患やがんの罹患率の増加により、早期かつ正確な診断が必要となっている
    • 調査とイノベーションに対する政府の資金提供と取り組みの増加
  • 抑制要因
    • 効果的な治療手順のための放射性同位元素の入手可能性と安定性の確保
  • 機会
    • 先進的な放射性トレーサーとイメージング技術の開発
    • 核イメージング分析における人工知能と機械学習アルゴリズムの統合
  • 課題
    • 熟練した専門家の不足が核医学ソリューションの効果的な展開に影響を与えている
• 市場セグメンテーション分析
  • 製品タイプ：疾患治療のための標的放射性化合物の治療核医学に対する需要の高まり
  • 投与方法：放射性医薬品を投与するための非侵襲的な代替手段として経口摂取が優先される
  • 用途：臓器機能を評価し、病理学的変化を特定するための診断手順の重要性
  • 使用性：がんの診断と管理のための腫瘍学アプリケーションにおける核医学の活用
  • エンドユーザー：診断センター全体で核医学の採用が拡大し、病気の正確な画像化と早期発見が可能に
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 核医学市場：製品タイプ別

• イントロダクション
• 診断用核医学
  • 陽電子放出断層撮影（PET）同位体
  • 単一光子放出コンピュータ断層撮影（SPECT）同位体
• 治療用核医学
  • 密封小線源治療用同位元素
    • セシウム131
    • ヨウ素125
    • イリジウム192
    • パラジウム103
  • 放射性医薬品療法
    • アルファ放射体
    • ベータ線放射体

第7章 核医学市場：投与方法別

• イントロダクション
• 静脈注射
• 経口摂取

第8章 核医学市場：用途別

• イントロダクション
• 診断手順
  • PETスキャナー
    • アナログPET
    • デジタルPET
  • SPECTスキャナー
• 治療手順

第9章 核医学市場：使用性別

• イントロダクション
• 心臓病学
• 内分泌学
• 消化器内科
• 神経学
• 腫瘍学
• 整形外科
• 呼吸器科

第10章 核医学市場：エンドユーザー別

• イントロダクション
• 学術研究機関
• 診断センター
• 病院
  • 公立病院
  • 私立病院

第11章 南北アメリカの核医学市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋の核医学市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカの核医学市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析、2024年
• FPNVポジショニングマトリックス、2024年
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• 3B Pharmaceuticals GmbH
• Actinium Pharmaceuticals, Inc.
• B J Madan & Co.
• Bayer AG
• Bracco S.p.A.
• BWX Technologies, Inc.
• Clarity Pharmaceuticals
• Curium
• Eli Lilly and Company
• GE HealthCare
• IBA
• Institute of Isotopes Co., Ltd
• Isotopia Molecular Imaging Ltd.
• Jubilant Pharma Limited
• Lantheus Holdings, Inc.
• Medi-Radiopharma Co., Ltd.
• Nordion
• Northstar Medical Technologies LLC
• Novartis AG
• Nusano, Inc.
• PeptiDream Inc.
• Radiopharm Theranostics Limited
• SHINE Technologies, LLC
• Siemens Healthineers AG
• Sinotau Pharmaceuticals Group
• South African Nuclear Energy Corporation
• State Atomic Energy Corporation Rosatom
• Thor Medical AS by Nordic Nanovector ASA

LIST OF FIGURES

• FIGURE 1. NUCLEAR MEDICINE MARKET MULTI-CURRENCY
• FIGURE 2. NUCLEAR MEDICINE MARKET MULTI-LANGUAGE
• FIGURE 3. NUCLEAR MEDICINE MARKET RESEARCH PROCESS
• FIGURE 4. NUCLEAR MEDICINE MARKET SIZE, 2024 VS 2030
• FIGURE 5. GLOBAL NUCLEAR MEDICINE MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 6. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
• FIGURE 9. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2030 (%)
• FIGURE 11. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2024 VS 2030 (%)
• FIGURE 13. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
• FIGURE 15. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 16. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2024 VS 2030 (%)
• FIGURE 17. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 18. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 19. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 20. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
• FIGURE 21. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 22. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 23. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 24. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 25. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 26. NUCLEAR MEDICINE MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 27. NUCLEAR MEDICINE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. NUCLEAR MEDICINE MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL NUCLEAR MEDICINE MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. NUCLEAR MEDICINE MARKET DYNAMICS
• TABLE 7. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY (PET) ISOTOPES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) ISOTOPES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY CESIUM-131, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY IODINE-125, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY IRIDIUM-192, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PALLADIUM-103, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ALPHA EMITTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY INTRAVENOUS INJECTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ORAL INGESTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ANALOG PET, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY DIGITAL PET, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY SPECT SCANNERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC PROCEDURE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 37. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 38. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 39. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY GASTROENTEROLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 40. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 41. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 42. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ORTHOPEDICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 43. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PULMONOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 44. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 45. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 46. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 47. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 48. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY GOVERNMENT HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 49. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 50. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 51. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 52. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
• TABLE 53. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2030 (USD MILLION)
• TABLE 54. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2030 (USD MILLION)
• TABLE 55. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 56. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 57. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
• TABLE 58. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2030 (USD MILLION)
• TABLE 59. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2030 (USD MILLION)
• TABLE 60. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 61. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 62. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 63. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 64. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 65. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
• TABLE 66. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2030 (USD MILLION)
• TABLE 67. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2030 (USD MILLION)
• TABLE 68. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 69. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 70. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
• TABLE 71. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2030 (USD MILLION)
• TABLE 72. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2030 (USD MILLION)
• TABLE 73. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 74. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 75. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 76. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 77. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
• TABLE 78. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2030 (USD MILLION)
• TABLE 79. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2030 (USD MILLION)
• TABLE 80. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 81. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 82. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
• TABLE 83. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2030 (USD MILLION)
• TABLE 84. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2030 (USD MILLION)
• TABLE 85. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 86. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 87. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 88. CANADA NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 89. CANADA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
• TABLE 90. CANADA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2030 (USD MILLION)
• TABLE 91. CANADA NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2030 (USD MILLION)
• TABLE 92. CANADA NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 93. CANADA NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 94. CANADA NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
• TABLE 95. CANADA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2030 (USD MILLION)
• TABLE 96. CANADA NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2030 (USD MILLION)
• TABLE 97. CANADA NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 98. CANADA NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 99. CANADA NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 100. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 101. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
• TABLE 102. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2030 (USD MILLION)
• TABLE 103. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2030 (USD MILLION)
• TABLE 104. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 105. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 106. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
• TABLE 107. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2030 (USD MILLION)
• TABLE 108. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2030 (USD MILLION)
• TABLE 109. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 110. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 111. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 112. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 113. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
• TABLE 114. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2030 (USD MILLION)
• TABLE 115. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2030 (USD MILLION)
• TABLE 116. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 117. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 118. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
• TABLE 119. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2030 (USD MILLION)
• TABLE 120. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2030 (USD MILLION)
• TABLE 121. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 122. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 123. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 124. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 125. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 126. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
• TABLE 127. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2030 (USD MILLION)
• TABLE 128. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2030 (USD MILLION)
• TABLE 129. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 130. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 131. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
• TABLE 132. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2030 (USD MILLION)
• TABLE 133. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2030 (USD MILLION)
• TABLE 134. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 135. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 136. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 137. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 138. AUSTRALIA NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 139. AUSTRALIA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
• TABLE 140. AUSTRALIA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2030 (USD MILLION)
• TABLE 141. AUSTRALIA NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2030 (USD MILLION)
• TABLE 142. AUSTRALIA NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 143. AUSTRALIA NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 144. AUSTRALIA NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
• TABLE 145. AUSTRALIA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2030 (USD MILLION)
• TABLE 146. AUSTRALIA NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2030 (USD MILLION)
• TABLE 147. AUSTRALIA NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 148. AUSTRALIA NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 149. AUSTRALIA NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 150. CHINA NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 151. CHINA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
• TABLE 152. CHINA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2030 (USD MILLION)
• TABLE 153. CHINA NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2030 (USD MILLION)
• TABLE 154. CHINA NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 155. CHINA NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 156. CHINA NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
• TABLE 157. CHINA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2030 (USD MILLION)
• TABLE 158. CHINA NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2030 (USD MILLION)
• TABLE 159. CHINA NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 160. CHINA NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 161. CHINA NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 162. INDIA NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 163. INDIA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
• TABLE 164. INDIA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2030 (USD MILLION)
• TABLE 165. INDIA NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2030 (USD MILLION)
• TABLE 166. INDIA NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 167. INDIA NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 168. INDIA NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
• TABLE 169. INDIA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2030 (USD MILLION)
• TABLE 170. INDIA NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2030 (USD MILLION)
• TABLE 171. INDIA NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 172. INDIA NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 173. INDIA NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 174. INDONESIA NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 175. INDONESIA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
• TABLE 176. INDONESIA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2030 (USD MILLION)
• TABLE 177. INDONESIA NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2030 (USD MILLION)
• TABLE 178. INDONESIA NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 179. INDONESIA NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 180. INDONESIA NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
• TABLE 181. INDONESIA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2030 (USD MILLION)
• TABLE 182. INDONESIA NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2030 (USD MILLION)
• TABLE 183. INDONESIA NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 184. INDONESIA NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 185. INDONESIA NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 186. JAPAN NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 187. JAPAN NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
• TABLE 188. JAPAN NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2030 (USD MILLION)
• TABLE 189. JAPAN NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2030 (USD MILLION)
• TABLE 190. JAPAN NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 191. JAPAN NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 192. JAPAN NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
• TABLE 193. JAPAN NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2030 (USD MILLION)
• TABLE 194. JAPAN NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2030 (USD MILLION)
• TABLE 195. JAPAN NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 196. JAPAN NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 197. JAPAN NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 198. MALAYSIA NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 199. MALAYSIA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
• TABLE 200. MALAYSIA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2030 (USD MILLION)
• TABLE 201. MALAYSIA NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2030 (USD MILLION)
• TABLE 202. MALAYSIA NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 203. MALAYSIA NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 204. MALAYSIA NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
• TABLE 205. MALAYSIA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2030 (USD MILLION)
• TABLE 206. MALAYSIA NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2030 (USD MILLION)
• TABLE 207. MALAYSIA NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 208. MALAYSIA NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 209. MALAYSIA NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 210. PHILIPPINES NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 211. PHILIPPINES NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
• TABLE 212. PHILIPPINES NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2030 (USD MILLION)
• TABLE 213. PHILIPPINES NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2030 (USD MILLION)
• TABLE 214. PHILIPPINES NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 215. PHILIPPINES NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 216. PHILIPPINES NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
• TABLE 217. PHILIPPINES NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2030 (USD MILLION)
• TABLE 218. PHILIPPINES NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2030 (USD MILLION)
• TABLE 219. PHILIPPINES NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 220. PHILIPPINES NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 221. PHILIPPINES NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 222. SINGAPORE NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 223. SINGAPORE NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
• TABLE 224. SINGAPORE NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2030 (USD MILLION)
• TABLE 225. SINGAPORE NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2030 (USD MILLION)
• TABLE 226. SINGAPORE NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 227. SINGAPORE NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 228. SINGAPORE NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
• TABLE 229. SINGAPORE NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2030 (USD MILLION)
• TABLE 230. SINGAPORE NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2030 (USD MILLION)
• TABLE 231. SINGAPORE NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 232. SINGAPORE NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 233. SINGAPORE NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 234. SOUTH KOREA NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 235. SOUTH KOREA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
• TABLE 236. SOUTH KOREA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2030 (USD MILLION)
• TABLE 237. SOUTH KOREA NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2030 (USD MILLION)
• TABLE 238. SOUTH KOREA NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 239. SOUTH KOREA NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 240. SOUTH KOREA NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
• TABLE 241. SOUTH KOREA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2030 (USD MILLION)
• TABLE 242. SOUTH KOREA NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2030 (USD MILLION)
• TABLE 243. SOUTH KOREA NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 244. SOUTH KOREA NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 245. SOUTH KOREA NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 246. TAIWAN NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 247. TAIWAN NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
• TABLE 248. TAIWAN NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2030 (USD MILLION)
• TABLE 249. TAIWAN NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2030 (USD MILLION)
• TABLE 250. TAIWAN NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 251. TAIWAN NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 252. TAIWAN NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
• TABLE 253. TAIWAN NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2030 (USD MILLION)
• TABLE 254. TAIWAN NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2030 (USD MILLION)
• TABLE 255. TAIWAN NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 256. TAIWAN NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 257. TAIWAN NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 258. THAILAND NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 259. THAILAND NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
• TABLE 260. THAILAND NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2030 (USD MILLION)
• TABLE 261. THAILAND NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2030 (USD MILLION)
• TABLE 262. THAILAND NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 263. THAILAND NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 264. THAILAND NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
• TABLE 265. THAILAND NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2030 (USD MILLION)
• TABLE 266. THAILAND NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2030 (USD MILLION)
• TABLE 267. THAILAND NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 268. THAILAND NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 269. THAILAND NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 270. VIETNAM NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 271. VIETNAM NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
• TABLE 272. VIETNAM NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2030 (USD MILLION)
• TABLE 273. VIETNAM NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2030 (USD MILLION)
• TABLE 274. VIETNAM NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 275. VIETNAM NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 276. VIETNAM NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
• TABLE 277. VIETNAM NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2030 (USD MILLION)
• TABLE 278. VIETNAM NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2030 (USD MILLION)
• TABLE 279. VIETNAM NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 280. VIETNAM NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 281. VIETNAM NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 282. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 283. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
• TABLE 284. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2030 (USD MILLION)
• TABLE 285. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2030 (USD MILLION)
• TABLE 286. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 287. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 288. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
• TABLE 289. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2030 (USD MILLION)
• TABLE 290. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2030 (USD MILLION)
• TABLE 291. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 292. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 293. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 294. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 295. DENMARK NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 296. DENMARK NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
• TABLE 297. DENMARK NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2030 (USD MILLION)
• TABLE 298. DENMARK NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2030 (USD MILLION)
• TABLE 299. DENMARK NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 300. DENMARK NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 301. DENMARK NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
• TABLE 302. DENMARK NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2030 (USD MILLION)
• TABLE 303. DENMARK NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2030 (USD MILLION)
• TABLE 304. DENMARK NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 305. DENMARK NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 306. DENMARK NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 307. EGYPT NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 308. EGYPT NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
• TABLE 309. EGYPT NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2030 (USD MILLION)
• TABLE 310. EGYPT NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2030 (USD MILLION)
• TABLE 311. EGYPT NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 312. EGYPT NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 313. EGYPT NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
• TABLE 314. EGYPT NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2030 (USD MILLION)
• TABLE 315. EGYPT NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2030 (USD MILLION)
• TABLE 316. EGYPT NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 317. EGYPT NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 318. EGYPT NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 319. FINLAND NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 320. FINLAND NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
• TABLE 321. FINLAND NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2030 (USD MILLION)
• TABLE 322. FINLAND NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2030 (USD MILLION)
• TABLE 323. FINLAND NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 324. FINLAND NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 325. FINLAND NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
• TABLE 326. FINLAND NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2030 (USD MILLION)
• TABLE 327. FINLAND NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2030 (USD MILLION)
• TABLE 328. FINLAND NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 329. FINLAND NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 330. FINLAND NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 331. FRANCE NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 332. FRANCE NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
• TABLE 333. FRANCE NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2030 (USD MILLION)
• TABLE 334. FRANCE NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2030 (USD MILLION)
• TABLE 335. FRANCE NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 336. FRANCE NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 337. FRANCE NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
• TABLE 338. FRANCE NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2030 (USD MILLION)
• TABLE 339. FRANC

The Nuclear Medicine Market was valued at USD 14.60 billion in 2024 and is projected to grow to USD 16.05 billion in 2025, with a CAGR of 10.80%, reaching USD 27.04 billion by 2030.

Executive Summary Introduction: Overview and Imperatives in Nuclear Medicine

Nuclear medicine has evolved into a cornerstone of modern healthcare, offering novel diagnostic and therapeutic solutions that are revolutionizing patient care. In an industry where accuracy, precision, and efficiency are paramount, this executive summary provides a clear and comprehensive overview of the current landscape. The content that follows lays the groundwork by addressing the critical factors underlying the market's evolution, including technological innovations, regulatory dynamics, and the shifting paradigms in treatment protocols. The insights herein are intended for decision-makers and industry experts alike, focusing on how emerging trends are setting new benchmarks in clinical practices and reshaping competitive strategies. This introduction establishes the context by describing how global trends such as increasing chronic diseases, a surge in personalized medicine, and renewed focus on early diagnostic interventions are catalyzing innovation in nuclear medicine. As healthcare systems worldwide continue to invest in advanced imaging and treatment modalities, the stage is set for strategic realignments that enhance patient outcomes and offer unprecedented opportunities for growth and collaboration.

Transformative Shifts in the Nuclear Medicine Landscape

The nuclear medicine landscape is experiencing transformative shifts that are redefining the boundaries of diagnostic and therapeutic care. These changes are driven largely by technological advances, evolving clinical guidelines, and increased regulatory support that together have accelerated the pace of innovation. One of the most significant drivers is the rapid development of cutting-edge radiopharmaceuticals and imaging techniques that are not only more accurate but also safer for patients. In recent years, a confluence of improved digital imaging technologies and enhanced targeting mechanisms has allowed for more precise detection of diseases, particularly in specialties such as oncology, cardiology, and neurology.

Regulatory bodies and healthcare policymakers have been instrumental in fostering this change by streamlining approval processes for new diagnostic agents and treatment protocols. This supportive framework has enabled manufacturers and research institutions to accelerate clinical trials and integrate advanced therapeutic approaches into routine practice. Moreover, the integration of artificial intelligence and machine learning in image analysis has empowered clinicians with sophisticated diagnostic tools, enhancing the accuracy of interpretations and offering deeper insights into disease progression.

Another notable shift is the growing emphasis on personalized medicine. The customization of treatment plans based on an individual's genetic profile and disease characteristics has become a central feature of modern nuclear medicine. This not only improves treatment outcomes but also contributes to the optimization of healthcare resources by minimizing trial-and-error approaches in patient care. The combined impact of these factors is a market that is more agile and responsive to the unique needs of each patient, setting the stage for sustained growth and innovation in the sectors of diagnostic and therapeutic interventions.

The evolving clinical demands and the relentless pursuit of precision in oncology, among other specialties, underscore the importance of robust research and development initiatives. These initiatives are pushing the envelope by extending the boundaries of what is clinically feasible and paving the way towards novel paradigms that merge traditional pharmaceutical practices with emerging radioactive therapies. As the market continues to evolve, stakeholders are increasingly leveraging data-driven insights to inform strategic decisions that enhance competitiveness and set new standards in patient care.

In-Depth Segmentation Insights Driving Market Decisions

Deep-dive segmentation across the nuclear medicine market reveals a multifaceted structure that underscores both the diversity and the growing complexity of this field. Examination of product type segmentation illustrates that the market is bifurcated into Diagnostic Radiopharmaceuticals and Therapeutic Nuclear Medicine. Diagnostic Radiopharmaceuticals encompass imaging modalities which are further subdivided into Positron Emission Tomography (PET) isotopes and Single Photon Emission Computed Tomography (SPECT) isotopes, each offering unique clinical advantages. On the other hand, Therapeutic Nuclear Medicine is characterized by its focus on treatment and includes two primary branches: brachytherapy isotopes and radiopharmaceutical therapy. The former is further nuanced by an emphasis on using isotopes such as Cesium-131, Iodine-125, Iridium-192, and Palladium-103, while the latter distinguishes between Alpha Emitters and Beta Emitters, each with specific radiobiological properties and therapeutic applications.

Beyond product categorization, the segmentation based on mode of administration brings to light critical considerations for effective treatment delivery. The market analysis compares the efficacy and patient compliance of intravenous injection versus oral ingestion, offering insights into which delivery modes best meet clinical needs while maximizing therapeutic outcomes. In addition, usage-based segmentation distinguishes between Diagnostic Procedures and Therapeutic Procedures. The diagnostic dimension is supported by advanced imaging technologies including PET scanners-differentiated into analog PET and digital PET-as well as SPECT scanners, highlighting the technological evolution and competitive dynamics within imaging equipment.

Furthermore, the application-based segmentation offers an expansive view that incorporates several clinical domains including cardiology, endocrinology, gastroenterology, neurology, oncology, orthopedics, and pulmonology. Each application area is characterized by distinct clinical challenges and opportunities, underscoring how nuclear medicine is tailored to address diverse patient needs. The ability to navigate across these clinical specialties not only enhances diagnostic precision but also facilitates a more effective treatment paradigm that is responsive to the nuanced characteristics of various diseases.

Lastly, segmentation based on end user outlines the diverse ecosystem comprising academic and research institutes, diagnostic centers, and hospitals-with hospitals being further differentiated into government and private sectors. This segmentation highlights how institutional preferences and budgetary constraints influence purchasing decisions and treatment protocols, ultimately driving the strategic priorities of stakeholders in the nuclear medicine domain. Insightful analysis of these segmentation layers supports targeted marketing and distribution strategies, ensuring that innovations in nuclear medicine achieve maximum clinical and commercial impact.

Based on Product Type, market is studied across Diagnostic Radiopharmaceuticals and Therapeutic Nuclear Medicine. The Diagnostic Radiopharmaceuticals is further studied across Positron Emission Tomography (PET) Isotopes and Single Photon Emission Computed Tomography (SPECT) Isotopes. The Therapeutic Nuclear Medicine is further studied across Brachytherapy Isotopes and Radiopharmaceutical Therapy. The Brachytherapy Isotopes is further studied across Cesium-131, Iodine-125, Iridium-192, and Palladium-103. The Radiopharmaceutical Therapy is further studied across Alpha Emitters and Beta Emitters.

Based on Mode Of Administration, market is studied across Intravenous Injection and Oral Ingestion.

Based on Usage, market is studied across Diagnostic Procedure and Therapeutic Procedure. The Diagnostic Procedure is further studied across PET Scanners and SPECT Scanners. The PET Scanners is further studied across Analog PET and Digital PET.

Based on Application, market is studied across Cardiology, Endocrinology, Gastroenterology, Neurology, Oncology, Orthopedics, and Pulmonology.

Based on End Users, market is studied across Academic & Research Institutes, Diagnostic Centers, and Hospitals. The Hospitals is further studied across Government Hospitals and Private Hospitals.

Key Regional Insights in the Evolving Nuclear Medicine Market

The geographic dimensions of the nuclear medicine market provide crucial insights into regional dynamics and growth opportunities. In the Americas, there is a marked increase in the adoption of advanced diagnostic and therapeutic solutions, driven by robust healthcare infrastructure and significant investments in research and innovation. This region is characterized by high levels of governmental support and a strong emphasis on cutting-edge technology, which together enable rapid integration of novel imaging and treatment protocols.

Moving to the Europe, Middle East & Africa region, one observes an equally dynamic landscape where innovation is often tempered by the need for cost-effective solutions. Here, regulatory frameworks and public-private partnerships play a central role in shaping market dynamics, encouraging the adoption of integrated healthcare solutions that balance quality with economic considerations. This region continues to witness significant advancements in both clinical practices and research, fostering an environment where collaborative initiatives spur technological breakthroughs.

In the Asia-Pacific region, the market is marked by rapid expansion and a growing appetite for technological adoption across both urban and rural healthcare settings. Significant investments in healthcare infrastructure, combined with increasing public awareness about early diagnostic interventions, are driving the widespread adoption of nuclear medicine technologies. Rapid urbanization and evolving healthcare policies have enabled more comprehensive patient care models that integrate state-of-the-art nuclear medicine diagnostics and treatments. Regional strategies are increasingly focusing on expanding access to advanced medical technologies, thereby aligning with the global trend of personalized and precision medicine. In sum, the regional analysis underlines how diverse socio-economic factors and distinct healthcare priorities are influencing market growth and fostering tailored strategies across the globe.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Leading Companies Shaping the Nuclear Medicine Sphere

The nuclear medicine market is characterized by an intricate network of established multinational corporations and agile companies that collectively push the boundaries of diagnostic and therapeutic innovation. Prominent players such as 3B Pharmaceuticals GmbH and Actinium Pharmaceuticals, Inc. have been instrumental in advancing cutting-edge radiopharmaceutical development. Other significant contributors include B J Madan & Co. and Bayer AG, who consistently drive market momentum through sustained investment in research and strategic collaborations. Renowned companies like Bracco S.p.A. and BWX Technologies, Inc. have carved out critical niches through innovations that have redefined imaging and therapeutic techniques. Clarity Pharmaceuticals and Curium stand out for their unique contributions in clinical research and advanced radiopharmaceutical applications.

Further enhancing the competitive landscape are global industry leaders such as Eli Lilly and Company, GE HealthCare, and IBA, whose extensive portfolios encompass both state-of-the-art diagnostic imaging and innovative therapeutic options. The contributions of institutions like the Institute of Isotopes Co., Ltd and Isotopia Molecular Imaging Ltd. underscore the importance of research-driven innovation, while Jubilant Pharma Limited and Lantheus Holdings, Inc. have earned recognition for their robust market presence and strategic acquisitions. Companies such as Medi-Radiopharma Co., Ltd. and Nordion continue to distinguish themselves with a focus on integrating breakthrough therapies into existing treatment frameworks.

In addition, the market is further diversified by players like Northstar Medical Technologies LLC and Novartis AG, who leverage global distribution networks and deep clinical expertise to capture emerging market segments. Nusano, Inc., PeptiDream Inc., and Radiopharm Theranostics Limited are recognized for their cutting-edge technological advancements and ability to address unmet clinical needs. Meanwhile, SHINE Technologies, LLC and Siemens Healthineers AG remain at the forefront by merging traditional imaging paradigms with digital innovations. Sinotau Pharmaceuticals Group, South African Nuclear Energy Corporation, and State Atomic Energy Corporation Rosatom continue to influence market dynamics through robust governmental backing and a focus on sustainable development. Finally, Thor Medical AS by Nordic Nanovector ASA adds a unique dimension with its specialized imaging solutions that cater to niche market segments. Collectively, these companies are not only responding to current clinical demands but are also paving the way for future innovations that will redefine patient care in nuclear medicine.

The report delves into recent significant developments in the Nuclear Medicine Market, highlighting leading vendors and their innovative profiles. These include 3B Pharmaceuticals GmbH, Actinium Pharmaceuticals, Inc., B J Madan & Co., Bayer AG, Bracco S.p.A., BWX Technologies, Inc., Clarity Pharmaceuticals, Curium, Eli Lilly and Company, GE HealthCare, IBA, Institute of Isotopes Co., Ltd, Isotopia Molecular Imaging Ltd., Jubilant Pharma Limited, Lantheus Holdings, Inc., Medi-Radiopharma Co., Ltd., Nordion, Northstar Medical Technologies LLC, Novartis AG, Nusano, Inc., PeptiDream Inc., Radiopharm Theranostics Limited, SHINE Technologies, LLC, Siemens Healthineers AG, Sinotau Pharmaceuticals Group, South African Nuclear Energy Corporation, State Atomic Energy Corporation Rosatom, and Thor Medical AS by Nordic Nanovector ASA. Actionable Strategic Recommendations for Industry Leaders

For industry leaders aiming to maintain a competitive advantage in the fast-evolving nuclear medicine market, several actionable recommendations should be considered. First, there is a clear need to invest strategically in research and development programs that focus on enhancing imaging resolution, minimizing radiation exposure, and improving the targeting accuracy of radiopharmaceutical agents. Such investments will not only foster innovation but will also ensure that products remain at the cutting edge of clinical utility.

Second, it is imperative to cultivate strategic partnerships with research institutions, technology providers, and healthcare organizations. Collaborations of this nature enable the pooling of expertise and resources, thereby accelerating the translation of novel diagnostics and therapeutics into clinical practice. Emphasis should be placed on forging alliances that span across geographical boundaries, ensuring that technological advancements are distributed efficiently and effectively across diverse healthcare ecosystems.

In addition, leaders should prioritize the implementation of integrated digital platforms that leverage artificial intelligence and machine learning for enhanced diagnostic precision and proactive patient management. These platforms can facilitate real-time data analytics, predictive modeling, and streamlined workflows that integrate seamlessly with existing clinical systems. Furthermore, by harnessing big data and advanced analytics, organizations can optimize resource allocation and tailor treatment protocols to individual patient profiles, thereby reinforcing the move towards personalized medicine.

There is also a strategic imperative to focus on market-specific tailoring of product portfolios. Understanding the nuances of segmentation-whether it is by product type, mode of administration, usage, application, or end user-allows organizations to develop solutions that are both clinically effective and commercially viable. Customizing products and services to meet the distinct needs of various geographic regions and healthcare institutions will enhance market penetration and foster long-term loyalty.

Moreover, regulatory compliance and proactive engagement with policy-makers remain critical. Transparent communication and compliance with evolving regulatory standards not only reduce legal risks but also build trust with stakeholders and end users. Organizations are advised to establish dedicated regulatory affairs teams that continuously monitor changes in the legal landscape and advocate for favorable policies that support industry innovation and patient safety.

Finally, there is a pressing need to embed sustainability into the core strategy. As the industry grapples with environmental and ethical considerations, adopting green technologies and sustainable practices can serve as a differentiator in an increasingly competitive market. Embracing sustainable production methods, reducing waste, and ensuring energy efficiency in manufacturing processes will not only reduce the ecological footprint but also resonate well with modern consumers and policymakers. These strategic recommendations offer a clear roadmap for industry leaders aiming to harness the full potential of the nuclear medicine market and secure leadership in a future defined by rapid technological innovation and complex clinical demands.

Conclusion: Charting a Forward-Looking Path in Nuclear Medicine

In conclusion, the nuclear medicine market is positioned at a critical juncture where transformative technological shifts, robust segmentation strategies, and dynamic regional trends converge to redefine the scope of diagnostic and therapeutic care. The detailed analysis presented in this executive summary highlights the significant strides made in radiopharmaceutical development, advanced imaging modalities, and personalized treatment approaches, while also providing a structured view of market segmentation that spans product types, modes of administration, clinical usage, and end user demographics. These insights underscore the industry's commitment to innovation and the continuous pursuit of enhanced patient outcomes amid rapidly evolving market conditions.

The extensive evaluation of regional markets, from the technologically advanced healthcare systems in the Americas to the cost-sensitive yet innovation-driven frameworks in Europe, the Middle East & Africa, and the rapidly expanding infrastructures in Asia-Pacific, reveals a truly global landscape that is both diverse and interconnected. Meanwhile, the competitive analysis of leading companies reiterates the pronounced role of strategic partnerships, technological integration, and robust R&D investments in navigating the complexities of this field.

As stakeholders grapple with the twin challenges of meeting rising clinical demands and addressing the economic pressures inherent in healthcare systems worldwide, the insights and recommendations provided herein serve as a reliable compass for charting the path forward. The integration of innovative diagnostic tools, the adaptation of sustainable practices, and the proactive engagement with regulatory frameworks are poised to drive the next phase of growth and value creation in nuclear medicine. The collective expertise of industry leaders, when channeled effectively, stands to revolutionize patient care, optimize resource utilization, and achieve unprecedented clinical outcomes in a market in constant flux.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of chronic diseases and cancer incidence necessitating early and accurate diagnostics
    • 5.1.1.2. Rising government funding and initiatives for nuclear medicine research and innovation
  • 5.1.2. Restraints
    • 5.1.2.1. Ensuring the availability and stability of radioactive isotopes for effective treatment procedures
  • 5.1.3. Opportunities
    • 5.1.3.1. Development of advanced radiotracers and imaging technology
    • 5.1.3.2. Integration of artificial intelligence and machine learning algorithms in nuclear imaging analysis
  • 5.1.4. Challenges
    • 5.1.4.1. Scarcity of skilled professionals impacting the effective deployment of nuclear medicine solutions
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product Type: Rising demand for therapeutic nuclear medicine for targeted radioactive compounds to treat diseases
  • 5.2.2. Mode Of Administration: Preference for oral ingestion for non-invasive alternative for administering radiopharmaceuticals
  • 5.2.3. Usage: Significance of diagnostic procedure for evaluating organ function and identifying pathological changes
  • 5.2.4. Application: Utilization of nuclear medicine in oncology applications for cancer diagnosis and management
  • 5.2.5. End Users: Increased adoption of nuclear medicine across diagnostic centers for precise imaging and early detection of diseases
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Nuclear Medicine Market, by Product Type

• 6.1. Introduction
• 6.2. Diagnostic Radiopharmaceuticals
  • 6.2.1. Positron Emission Tomography (PET) Isotopes
  • 6.2.2. Single Photon Emission Computed Tomography (SPECT) Isotopes
• 6.3. Therapeutic Nuclear Medicine
  • 6.3.1. Brachytherapy Isotopes
    • 6.3.1.1. Cesium-131
    • 6.3.1.2. Iodine-125
    • 6.3.1.3. Iridium-192
    • 6.3.1.4. Palladium-103
  • 6.3.2. Radiopharmaceutical Therapy
    • 6.3.2.1. Alpha Emitters
    • 6.3.2.2. Beta Emitters

7. Nuclear Medicine Market, by Mode Of Administration

• 7.1. Introduction
• 7.2. Intravenous Injection
• 7.3. Oral Ingestion

8. Nuclear Medicine Market, by Usage

• 8.1. Introduction
• 8.2. Diagnostic Procedure
  • 8.2.1. PET Scanners
    • 8.2.1.1. Analog PET
    • 8.2.1.2. Digital PET
  • 8.2.2. SPECT Scanners
• 8.3. Therapeutic Procedure

9. Nuclear Medicine Market, by Application

• 9.1. Introduction
• 9.2. Cardiology
• 9.3. Endocrinology
• 9.4. Gastroenterology
• 9.5. Neurology
• 9.6. Oncology
• 9.7. Orthopedics
• 9.8. Pulmonology

10. Nuclear Medicine Market, by End Users

• 10.1. Introduction
• 10.2. Academic & Research Institutes
• 10.3. Diagnostic Centers
• 10.4. Hospitals
  • 10.4.1. Government Hospitals
  • 10.4.2. Private Hospitals

11. Americas Nuclear Medicine Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Nuclear Medicine Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Nuclear Medicine Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2024
• 14.2. FPNV Positioning Matrix, 2024
• 14.3. Competitive Scenario Analysis
  • 14.3.1. Eletronuclear and the Brazilian Society of Nuclear Medicine have signed an agreement to evaluate the production of radioisotopes
  • 14.3.2. NorthStar Medical Radioisotopes join forces with YAP Therapeutics
  • 14.3.3. BWXT's USD 525 million to acquire Kinectrics to strengthens lifecycle management and nuclear isotope production capabilities
  • 14.3.4. Jubilant Radiopharma and Simplified Imaging Solutions announce strategic partnership to enhance the nuclear medicine
  • 14.3.5. NorthStar Medical Radioisotopes inaugurates CDMO facility in Beloit
  • 14.3.6. Saskatchewan USD 400,000 investment at Fedoruk Centre to drive nuclear medicine research
  • 14.3.7. Novartis invests over USD 150 million in expanding its Indianapolis nuclear medicine facility
  • 14.3.8. K S Hegde Hospital announces advancements in nuclear medicine
  • 14.3.9. MURR's strategic integration into nuclear medicine Europe enhances global radiopharmaceutical research and sustainable isotope production
  • 14.3.10. deepc Partners with PAIRE to innovate nuclear medicine
• 14.4. Strategy Analysis & Recommendation
  • 14.4.1. Jubilant Pharma Limited
  • 14.4.2. Curium
  • 14.4.3. Bracco S.p.A.
  • 14.4.4. Lantheus Holdings, Inc.

Companies Mentioned

• 1. 3B Pharmaceuticals GmbH
• 2. Actinium Pharmaceuticals, Inc.
• 3. B J Madan & Co.
• 4. Bayer AG
• 5. Bracco S.p.A.
• 6. BWX Technologies, Inc.
• 7. Clarity Pharmaceuticals
• 8. Curium
• 9. Eli Lilly and Company
• 10. GE HealthCare
• 11. IBA
• 12. Institute of Isotopes Co., Ltd
• 13. Isotopia Molecular Imaging Ltd.
• 14. Jubilant Pharma Limited
• 15. Lantheus Holdings, Inc.
• 16. Medi-Radiopharma Co., Ltd.
• 17. Nordion
• 18. Northstar Medical Technologies LLC
• 19. Novartis AG
• 20. Nusano, Inc.
• 21. PeptiDream Inc.
• 22. Radiopharm Theranostics Limited
• 23. SHINE Technologies, LLC
• 24. Siemens Healthineers AG
• 25. Sinotau Pharmaceuticals Group
• 26. South African Nuclear Energy Corporation
• 27. State Atomic Energy Corporation Rosatom
• 28. Thor Medical AS by Nordic Nanovector ASA